Improving treatment for triple-negative breast cancer using anti-NMDAR antibodies

Who could benefit from this research

What this research studies

This research focuses on developing a new therapy for triple-negative breast cancer (TNBC) by utilizing antibodies that target the N-methyl-D-aspartate receptor (NMDAR), which is often overexpressed in TNBC cells. The study aims to differentiate the anti-tumor effects of these antibodies from their potential neurological side effects, which can include severe complications like psychosis and seizures. Researchers will use advanced imaging techniques to understand how these antibodies interact with NMDAR and will test their effectiveness in specially designed mouse models of TNBC. The goal is to create a safe and effective treatment option for patients with this aggressive form of breast cancer.

Why it matters

Where this research is happening

• Cold Spring Harbor Laboratory
  Cold Spring Harbor, United States Active

Researchers

• Principal investigator: Janowitz, Tobias — Cold Spring Harbor Laboratory
• Study coordinator: Janowitz, Tobias

Related research

Other NIH-funded projects on the same topics.

• Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry

  This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.

  NIH research Tuskegee University · Tuskegee Institute, United States · NIH-11621786

• Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans

  A study aims to block two cancer-promoting pathways (IL-6 and CDK4/6) to prevent or reduce progression of triple-negative breast cancer in women veterans.

  NIH research Baltimore VA Medical Center · Baltimore, United States · NIH-11608792

• Linking heavy metal exposure to a tougher breast cancer type (TNBC)

  Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

  NIH research University of Louisville · Louisville, United States · NIH-11567535

• Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate

  Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11531542

• Rac-enhanced CAR-Macrophages against TNBC

  A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

  NIH research University of Louisville · Louisville, United States · NIH-11520503

• A new peptide therapy to help treat metastatic triple-negative breast cancer

  A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11453153

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.